Lynx1 Capital Management LP Stoke Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $515 Million
- Q3 2025
A detailed history of Lynx1 Capital Management LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,404,674 shares of STOK stock, worth $143 Million. This represents 24.66% of its overall portfolio holdings.
Number of Shares
5,404,674
Previous 5,404,674
-0.0%
Holding current value
$143 Million
Previous $61.3 Million
107.05%
% of portfolio
24.66%
Previous 18.16%
Shares
7 transactions
Others Institutions Holding STOK
# of Institutions
160Shares Held
60.2MCall Options Held
563KPut Options Held
101K-
Black Rock Inc. New York, NY5.41MShares$143 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$136 Million1.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$123 Million0.89% of portfolio
-
Redmile Group, LLC San Francisco, CA4.18MShares$111 Million10.81% of portfolio
-
Morgan Stanley New York, NY3.54MShares$93.8 Million0.01% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.05B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...